SUBJECT INDEX

Note: Glossary is located on pages xviii–xix

Abbott PRISM system, 170–171
ABO incompatible transfusions, 307
Access immunoassay system, 171
acetate, human albumin safety, 264
acquired immunodeficiency syndrome (AIDS) see AIDS
a determinant, hepatitis B, 161
adsorption techniques, virus removal, 275–276
chromatography, 276
depth filtration, 275–276
adverse event/reactions, 366
Advia Centaur immunoassay system, 171
Africa, blood safety, 372–376
cost, 217–218
organization, 373
transfusion-transmissible infections, 373
AIDS
toxoplasmosis, 125
transmission by plasma products, 263–264
risk management, 343–344
see also HIV
alanine aminotransferase (ALT), hepatitis viruses, 9, 196
albumin, human
processing, 259, 275, 276
safety, 264–265
acetate preparations, 264
Cohn fractions, 264
cold ethanol fractionation, 265
HIV, 265
pasterization, 264, 265, 271
algorithms, confirmatory testing see confirmatory algorithms
allogeenic transfusion, risk management, 353
American trypanosomiasis see Chagas' disease
aminotransferase levels
hepatitis B virus, 14
hepatitis C virus, 17
amotosalen (S59), 247–249
fresh frozen plasma treatment, 250
clinical studies, 252
reduction factors, 246
platelet treatments, 247–249
amplicons, polymerase chain reaction contamination, 187
detection, 184–185
AmpliCor extraction system, 213
amplification
microarrays, 232
nucleic acids see specific techniques
AmpliScreen system
extraction performance, 212
invalid runs, 213
protocol, 214
Andean Countries Initiative, Chagas' disease, 128
animal models, cytomegalovirus, 49
anti HAV, 11
antibody mediated virus neutralization, 14, 15, 23–34, 313
anti-D, hepatitis C transmission, 266
anti-E, HBV virus C/hepatitis G virus, 76
antigen(s)
recombinant, 227
sandwich assays, 162–163
antiglobulin test(s), 227
antiglobulin tests, 162
anti-HAV, 11
anti-HBc, 14, 15, 23–34, 313
anti-HBs, absence, 26–29
anti-HBs, 161
donor studies, 28
limitations, 30–31
nucleic acid testing coupling, 204–205
nucleic acid testing rs, 29–30
anti-HBs screening, 313
anti-HBc, 161
levels >100UI/L, 28
anti-HCV, 17
screening, 9, 175, 284
anti-HIV tests, 162
kit comparisons, 165
p24 antigen, 160
apheresis, 249
platelet concentrations, 94, 95
Architect immunoassay system, 178
archived blood samples, 312
arthritis, parvovirus B19, 68
Asia, blood safety, 389–372
blood procurement, 370
transfusion-transmitted infections, 378–372
assay(s)
closed systems, 222
design, 219–228
process control, 220
reagent presentation, 219
reagent volumes, 219
repeat tests, 165, 219
sample incubation, 229
sample volumes, 219
usability, 219–220
evaluation, 220–221
operational, 221
‘paper,’ 221
parameters, 220–221
minimal detectable limits, 282
nucleic acid testing, UK, 210–215
open systems, 222
performance, 223, 224–225
sensitivity, 221, 229
specificity, 220
see also specific assays
Australia antigens see hepatitis B virus
autoregulation, 287
autologous blood transfusion, 353
donor bacteraemia, 88
EU definition, 366
automation
blood cultures, 98–100
calibration, 222
drug linked immunosorbent assays, 165–166
limitations, 222
maintenance, 222
nucleic acid testing, 200
extraction, 211
screening quality, 222
staff knowledge/skills, 225–226
width, 222
enzymes, 222
EU definition, 366
nucleic acid testing, 200
screening quality, 222
staff knowledge/skills, 225–226
avian influenza, 88
Assam immunoassay system, 170
Babesia, 122–125
characteristics, 123
edemic areas, blood collection avoidance, 124
historical aspects, 122
immunofluorescence assay, 123
life cycle, 122
nucleic acid testing, 123
prevalence studies, 123
risk factors, 124
seroprevalence studies, 124
transfusion-transmitted, 124
Babesia divergens, 123, 124
Babesia microti, 124
babesiosis, 122–125
diagnosis, 123
‘gold standard’ test, 123
human infection, 123
transmission, 122
BacT/ALERT System, 98–100
bacterial detection algorithm, 100
bacterial screening data, 101
Pall eBDS system rs, 101, 102
confirmatory algorithms, 173–177, 236–237
BacT/ALERT, 100
hepatitis B virus, 174
hepatitis C virus, 174–176
HIV, 176
syphilis, 176
technology, impacts on, 238–237
confirmatory testing (screening), 173–180
algorithms see confirmatory algorithms
confirmed infection rate, 180
importance, 181
inconclusive results, 176–179
atypical patterns, 178–179
spurious blot/lime assay bands, 177
levels, 174
limitations, 203
principles, 173–174
congenital coagulation factor deficiency, 344
consumer protection, European Union legislation, 366–367
contact spotting, microarray technology, 232
contamination
controls, nucleic acid testing, 187–188
equipment, blood/blood components, 88–89
prion removal, 287
cost-effectiveness (CE) analysis
regulatory requirements, 358
risk management, 356–357, 358
transfusion safety interventions, 357–359
Council of Europe (CoE), 364
European Union distinction, 363–364
haemoglobin levels, 153
haemoglobinopathy, 305
leucocyte depletion, 239
voluntary non-renumerated donors, 153
Cossack B (Cox B) virus, 4–5
Creutzfeldt–Jakob disease (CJD)
blood product management, 147
familial, 142, 143
pathophysiology, 143
sporadic, 141, 143
tissue product management, 147
variant see variant Creutzfeldt–Jakob disease (vCJD)
cryo precipitate production, 252
haemophilia treatment, 267–268
crystal violet, Chagas’ disease, 130, 131
cytomegalovirus (CMV), 4–5, 35–50
animal models, 49
breakthrough infections
seronegative patients, 47–48
WBC reduction components, 47–48
characteristics, 4–5, 35–36
detection tests, 37–39
antibody screening, 37–38, 159, 163
antigen detection, 39
molecular amplification, 39
viral culture, 39
disease definition, 43
DNA detection, 38–39
immunosuppression, 240
infected blood, transmission, post-storage
filtration, 240
leucocyte depletion, 239–241
renal infection, exchange transfusion, 41
nucleic acid testing, 197
pathogen reduction, 244, 246
prestorage WBC reduction, 42
primary infection, 240
reactivation, allergic transfusion, 49–50
seroconversion, 35, 36, 39
transfusion-acquired infection
animal models, 41
blood donor associations, 40–41
clinical manifestations, 36–37
non-white blood cell components, 39–42
seronegative patients, 43–48
studies, 40–41, 45–47
transfusional component associations, 42
transfusion recipient associations, 41–42
unscreened components, 39–42
white blood cell reduced components, 43–48
deglycerolized blood, transfusion-transmission
infection, 52
delta virus see hepatitis D virus
Department of Health (DoH), plasma fractionation
restrictions, 209
depth filtration
prion removal, 287
virus removal, 275–276
developing countries, blood safety, 369–380
development, 369
prevalence, 369
see also individual countries/continents
diagnostics
biochips, 229–230
biosensors, 229–230
diagnostics, 228–233
microarrays see microarrays
see also specific assays
dielectricphoresis, Bac-Detect system, 103
directed blood donations, 154
disability adjusted life years (DALYs), Chagas’
disease, 128
disinfection
dimped phlebotomy sites, 87
donor arm, 87
improvement strategies, 91–92
diversion, bacterial contamination, 92–93
DNA microarrays, 232–233
probes, 230
donation testing, European Union
donation testing, 230
legislation, 367
donor arm, bacterial contamination, 87
improvement strategies, 91–92
bacterial infection, 87
bacterial contamination, 87
bacterial illness, 87
chronic low grade infection, 87
enteric organisms, 88
Salmonella enteritis, 88
transient bacteremia, 88
Yersinia enterocolitica, 88
donor re-admission, 180–182
minimal deferral period, 180
regular donors, 180
see also specific viruses
drug abuse, transfusion-transmissible infection
risks, 156
dry heat treatment
factor VIII, 268
fibrinogen, 271–272
virus inactivation processes, 270–272
virus validation studies, 282
EIA see enzyme immunoassay (EIA)
ELISA see enzyme linked immunosorbent assay (ELISA)
endotoxin detection, bacterial contamination, 97
enzyme immunoassay (EIA), 169
 assay design, 219
disparate results, 177
hepatitis B surface antigen, 14
human immunodeficiency virus-1, 60
enzyme linked immunosorbent assay (ELISA), 160,
164–166
automation, 165–166
hepatitis B surface antigen, 14
kit selection, 164–165
test performance, 165
episode protection assay, prion diseases, 150
Epstein–Barr virus (EBV), 50–52
characteristics, 50
high risk patients, WBC-reduced component
issues, 52
transfusion-transmission
children, 51
clinical manifestations, 50–51
frozen and deglycerolized blood, 52
prevention, 51–52
erythema infection, parovirus B19, 69
eurthroid differentiation associated factor (EDAF),
prion diseases, 146
euhrviruses, parovirus B19, 68, 71
escape mutants, hepatitis B, 161
ethanol fractionation, 275
ethylenimine oligomers, 253
European Agency for the Evaluation of Medicine
(EMEA), 183
European Pharmacopoeia (Ph Eur), 364
HCV nucleic acid testing, 193
European Union (EU)
Council of Europe distinction, 363–364
directives see European Union Directives
2004/33/EC, 367
paid donations, 154
transfusion-transmissible infection risks, sexual
behaviour, 156
European Union Directive (2002), 154
European Union Directives
85/374/EC, defective products, 366
98/79/EC, tissues/medical devices, 365
2000/70/EC, medical devices, 365
2001/83/EC, medicinal products, 364–365
2002/98/EC, blood/blood components, 365, 366
2003/94/EC, medicinal products, 365
2004/23/EC, tissues, 365
2004/33/EC, blood/blood components, 367
2006/17/EC, tissues, 365
definitions, 366
implementation, 367
European Union legislation, personnel, 366
Europe, regulatory environment see regulatory
environment, Europe
EuroSPRITE clinical study, 248
external quality assessment schemes (EQAS), 223–224
extraction systems, Amplicore, 213
<table>
<thead>
<tr>
<th>Subject index</th>
</tr>
</thead>
<tbody>
<tr>
<td>factor VIII haemophilia treatment, 267–270</td>
</tr>
<tr>
<td>haemophilia treatment, 267–270</td>
</tr>
<tr>
<td>hepatitis transmission, 11, 12, 270</td>
</tr>
<tr>
<td>history, 267–270</td>
</tr>
<tr>
<td>HIV transmission, 272</td>
</tr>
<tr>
<td>inhibitors, 269, 271</td>
</tr>
<tr>
<td>ion exchange purification, 277</td>
</tr>
<tr>
<td>methylene blue fresh frozen plasma treatment, 250</td>
</tr>
<tr>
<td>stabilisation, 270–271</td>
</tr>
<tr>
<td>factor IX, thrombogenicity, 272</td>
</tr>
<tr>
<td>fainting (delayed), blood donors, 155</td>
</tr>
<tr>
<td>false-negative antibody tests, 312</td>
</tr>
<tr>
<td>Fernandes, Pete, factor VIII stabilisation, 271</td>
</tr>
<tr>
<td>fetal infection, parvovirus B19, 69</td>
</tr>
<tr>
<td>fibrinogen</td>
</tr>
<tr>
<td>cryoprecipitate use, 252</td>
</tr>
<tr>
<td>dry heat treatment, 271</td>
</tr>
<tr>
<td>methylene blue fresh frozen plasma treatment, 250</td>
</tr>
<tr>
<td>fibrinolytic pathway inhibitors, 251</td>
</tr>
<tr>
<td>fifth disease, parvovirus B19, 68, 69</td>
</tr>
<tr>
<td>filtration</td>
</tr>
<tr>
<td>cytomegalovirus infected blood, 240</td>
</tr>
<tr>
<td>post-storage, 239, 240</td>
</tr>
<tr>
<td>depth</td>
</tr>
<tr>
<td>priors removal, 287</td>
</tr>
<tr>
<td>virus removal, 275–276</td>
</tr>
<tr>
<td>human T-cell leukaemia virus infected blood, 240</td>
</tr>
<tr>
<td>vCDI infected blood, 241</td>
</tr>
<tr>
<td>Flavivirus, 16, 73, 76</td>
</tr>
<tr>
<td>flow cytometry, 105</td>
</tr>
<tr>
<td>fluorescence immunoassay (FIA), 160</td>
</tr>
<tr>
<td>fluorophores, nucleic acid testing, 189</td>
</tr>
<tr>
<td>microarray use, 232</td>
</tr>
<tr>
<td>fetal bovine serum (FBS), 285</td>
</tr>
<tr>
<td>follicular dendritic cells, prion diseases, 142</td>
</tr>
<tr>
<td>Food and Drugs Administration (FDA)</td>
</tr>
<tr>
<td>bacterial contamination reports, 87</td>
</tr>
<tr>
<td>parvovirus B19V, 71</td>
</tr>
<tr>
<td>fourth generation assays see combination assay(s)</td>
</tr>
<tr>
<td>fractionated products, 259–304</td>
</tr>
<tr>
<td>antibody mediated virus neutralization, 274, 284</td>
</tr>
<tr>
<td>categories, 259</td>
</tr>
<tr>
<td>emerging viruses, 284</td>
</tr>
<tr>
<td>history, 259, 282–284</td>
</tr>
<tr>
<td>operational considerations, 282–283</td>
</tr>
<tr>
<td>plasma fractionation, 259–262</td>
</tr>
<tr>
<td>processes, 261–262</td>
</tr>
<tr>
<td>plasma testing, 260–261</td>
</tr>
<tr>
<td>pooling, 259, 261</td>
</tr>
<tr>
<td>priors see prion(s)</td>
</tr>
<tr>
<td>recombinant coagulation factor concentrates, 285</td>
</tr>
<tr>
<td>risk assessments, 283–284</td>
</tr>
<tr>
<td>risks associated, 259</td>
</tr>
<tr>
<td>UK, 260</td>
</tr>
<tr>
<td>virus inactivation processes, 278–274</td>
</tr>
<tr>
<td>virus removal, 275–277</td>
</tr>
<tr>
<td>virus validation studies see validation, virus studies</td>
</tr>
<tr>
<td>Frangible Anchor Liner Effector (FRALE), 108–109</td>
</tr>
<tr>
<td>French Haemovigilance scheme (BACTHEM), 87, 89, 306</td>
</tr>
<tr>
<td>fresh frozen plasma (FFP), 249–252</td>
</tr>
<tr>
<td>amotosalen, 250</td>
</tr>
<tr>
<td>clinical studies, 251–252</td>
</tr>
<tr>
<td>methylene blue, 249–250</td>
</tr>
<tr>
<td>solvent detergent, 242, 249</td>
</tr>
<tr>
<td>gametocytes, malaria, 118</td>
</tr>
<tr>
<td>Gammagard SD, 266–267</td>
</tr>
<tr>
<td>gamma irradiation, parvovirus B19, 68</td>
</tr>
<tr>
<td>GB virus C/hepatitis G virus (GBV-C/HGV), 75–77, 263</td>
</tr>
<tr>
<td>characteristics, 75</td>
</tr>
<tr>
<td>coincidences, 77</td>
</tr>
<tr>
<td>diagnosis, 77</td>
</tr>
<tr>
<td>genotypes, 75</td>
</tr>
<tr>
<td>geographic distribution, 76</td>
</tr>
<tr>
<td>HIV infection, 77</td>
</tr>
<tr>
<td>natural history, 75–76</td>
</tr>
<tr>
<td>pathogenicity, 77</td>
</tr>
<tr>
<td>HIV infection, 77</td>
</tr>
<tr>
<td>in transfusion, 76–77</td>
</tr>
<tr>
<td>transmission, 76</td>
</tr>
<tr>
<td>genomics, 229</td>
</tr>
<tr>
<td>German Transfusion Services, nucleic acid testing, 194</td>
</tr>
<tr>
<td>HAV, 196–197</td>
</tr>
<tr>
<td>parvovirus B19, 196–197</td>
</tr>
<tr>
<td>Gerstmann-Straussler-Scheinker disease (GSS), 144</td>
</tr>
<tr>
<td>Fukushima I strain, 144</td>
</tr>
<tr>
<td>glucose testing, bacterial contamination, 104</td>
</tr>
<tr>
<td>glycerol, factor VIII stabilisation, 270–271</td>
</tr>
<tr>
<td>good laboratory practice (GLP), 281–282</td>
</tr>
<tr>
<td>granulocyte transfections, cytomegalovirus reactivation, 48</td>
</tr>
<tr>
<td>‘grey zones,’ validation criteria, 224</td>
</tr>
<tr>
<td>growth media, recombinant coagulation factor concentrates, 285</td>
</tr>
<tr>
<td>H,N, influenza virus, 84</td>
</tr>
<tr>
<td>haemagglutination test(s), 167–169</td>
</tr>
<tr>
<td>hepatitis, 169</td>
</tr>
<tr>
<td>indirect, Chagas’ disease, 131</td>
</tr>
<tr>
<td>syphilis antibodies, 169</td>
</tr>
<tr>
<td>haematophasagous invertebrates, Trypanosoma cruzi, 128</td>
</tr>
<tr>
<td>haemolytic disease, parvovirus B19, 68</td>
</tr>
<tr>
<td>haemophilia</td>
</tr>
<tr>
<td>forms, 267</td>
</tr>
<tr>
<td>HIV transmission risk, 62</td>
</tr>
<tr>
<td>treatment, 267–270</td>
</tr>
<tr>
<td>cryoprecipitate, 267</td>
</tr>
<tr>
<td>vaccination, 271</td>
</tr>
<tr>
<td>haemovigilance, 228, 305–310</td>
</tr>
<tr>
<td>decision making, 309</td>
</tr>
<tr>
<td>definitions, 305, 366</td>
</tr>
<tr>
<td>European Union legislation, 366</td>
</tr>
<tr>
<td>French scheme, 87, 89, 306</td>
</tr>
<tr>
<td>goals, 305</td>
</tr>
<tr>
<td>screening quality, 228</td>
</tr>
<tr>
<td>SHOT see Serious Hazards of Transfusion (SHOT)</td>
</tr>
<tr>
<td>UK scheme, 306</td>
</tr>
<tr>
<td>HBsAg (hepatitis B surface antigen), 13</td>
</tr>
<tr>
<td>HCVAg (hepatitis C antigen), 17, 18</td>
</tr>
<tr>
<td>health and safety, pathogen reduction, 254</td>
</tr>
<tr>
<td>Health Council of the Netherlands, parvovirus B19V, 71</td>
</tr>
<tr>
<td>Hepatitis A virus (HAV), 9–12</td>
</tr>
<tr>
<td>hepatitis</td>
</tr>
<tr>
<td>fractionated products, transmission via, 259, 262–263</td>
</tr>
<tr>
<td>coagulation factors, 269</td>
</tr>
<tr>
<td>Cohn fractions, 262, 267, 275</td>
</tr>
<tr>
<td>immunoglobulins, 285</td>
</tr>
<tr>
<td>haemagglutination tests, 167–169</td>
</tr>
<tr>
<td>iatrogenic transmission, 262</td>
</tr>
<tr>
<td>infectious agents, 262–263</td>
</tr>
<tr>
<td>non-A, non-B, 9, 267, 274</td>
</tr>
<tr>
<td>vaccine transmitted, 262</td>
</tr>
<tr>
<td>viruses, 9–23</td>
</tr>
<tr>
<td>ALT levels, 9</td>
</tr>
<tr>
<td>anti-HCV testing, 9</td>
</tr>
<tr>
<td>emerging, 20</td>
</tr>
<tr>
<td>historical aspects, 9</td>
</tr>
<tr>
<td>transfusion-transmitted, 9, 10</td>
</tr>
<tr>
<td>see also specific viruses</td>
</tr>
<tr>
<td>hepatitis A virus (HAV), 9–12</td>
</tr>
<tr>
<td>anion exchange chromatography, 276</td>
</tr>
<tr>
<td>antibody neutralization, 273–274</td>
</tr>
<tr>
<td>characteristics, 9–10</td>
</tr>
<tr>
<td>clinical features, 10–11</td>
</tr>
<tr>
<td>definition, 9–10</td>
</tr>
<tr>
<td>diagnostic testing, 11</td>
</tr>
<tr>
<td>fibrogen, dry heat treatment, 271</td>
</tr>
<tr>
<td>infection risk factors, 11</td>
</tr>
<tr>
<td>life cycle, 10</td>
</tr>
<tr>
<td>nucleic acid testing, 196–197</td>
</tr>
<tr>
<td>United States approach, 206–207</td>
</tr>
<tr>
<td>seroconversion, 10</td>
</tr>
<tr>
<td>transfusion-transmission risk, 11–12</td>
</tr>
<tr>
<td>outbreaks, 12</td>
</tr>
<tr>
<td>transmission, 344</td>
</tr>
<tr>
<td>fractionated products, 263</td>
</tr>
<tr>
<td>solvent detergent treated products, 273–274</td>
</tr>
<tr>
<td>vaccine, 12</td>
</tr>
<tr>
<td>viroemia duration, 207</td>
</tr>
<tr>
<td>window period, 11</td>
</tr>
<tr>
<td>hepatitis B core antigen (HBcAg), 169</td>
</tr>
<tr>
<td>anti-HBc vs. anti-HBs, 161</td>
</tr>
<tr>
<td>hepatitis B core antibody (anti-HBc) see also specific viruses</td>
</tr>
<tr>
<td>hepatitis B e antigen (HBeAg), 13</td>
</tr>
<tr>
<td>hepatitis B surface antibody (anti-HBs) see also specific viruses</td>
</tr>
<tr>
<td>hepatitis B surface antigen (HBsAg), 13, 25, 161</td>
</tr>
<tr>
<td>absence</td>
</tr>
<tr>
<td>anti-HBc issues, 26–29</td>
</tr>
<tr>
<td>hepatitis B virus issues, 26–29</td>
</tr>
<tr>
<td>anion exchange chromatography, 276</td>
</tr>
<tr>
<td>blood donation screening, 14</td>
</tr>
<tr>
<td>confirmatory algorithms, 174, 175</td>
</tr>
<tr>
<td>diagnostic testing, 14</td>
</tr>
<tr>
<td>risk assessment calculation, 332</td>
</tr>
<tr>
<td>screening, 14, 228</td>
</tr>
<tr>
<td>anti-HBs vs. anti-HBc, 161</td>
</tr>
<tr>
<td>enzyme linked immunosorbent assay, 160</td>
</tr>
<tr>
<td>kit test comparisons, 165</td>
</tr>
<tr>
<td>nucleic acid testing vs. antigen tests, 195</td>
</tr>
<tr>
<td>reverse passive haemagglutination assay, 167–169</td>
</tr>
<tr>
<td>hepatitis B virus (HBV), 12–16</td>
</tr>
<tr>
<td>acute infection, 13–14</td>
</tr>
<tr>
<td>diagnosis, 14</td>
</tr>
<tr>
<td>inapparent, 313</td>
</tr>
<tr>
<td>jaundice, 13</td>
</tr>
<tr>
<td>anti-HBc presence, 26–29</td>
</tr>
<tr>
<td>anti-HBs absence, 26–29</td>
</tr>
</tbody>
</table>

© in this web service Cambridge University Press & Assessment

www.cambridge.org
characteristics, 12–13
chronic infection, 13
clinical features, 13–14
confirmatory algorithms, 174, 175
definition, 12–13
detection limits, 195
diagnostic testing, 14–15, 313
DNA, 25
DNA studies, 27, 30
donor re-admission, 180
escape mutants, 161
exsanguicidal complications, 13
fractionated products, removal, 275
genome, 13
HDV coinfection, 263
incidence, 333
incubation period, 13
nucleic acid testing, 15, 16, 193–194
anti-HKc coupling, 204–205
HBsAg testing vs., 195
United States approach, 204–205
perinatal transmission, 12
post-transfusion infection investigation, 313
prevalence, 12
risk assessment calculation, 337
risk factors, 15
seroconversion, 195–196
serology, 14, 25
single donor unit testing vs. mini-pooling, 16
transfusion-transmission risk, 15–16
residual, 25–26
vaccine, 16
viraemia levels, 12
window period, 15
see also associated antigens
hepatitis C (anti-HCVAg), 17, 18
hepatitis C virus (HCV), 16–19, 267
characteristics, 16–17
clinical features, 17
coinfection, 17
confirmatory algorithms, 174–176
definition, 16–17
definitive diagnosis, 17
diagnostic testing, 17–18
aminotransferase levels, 17
antibodies, 162
antigens, 160
donor readmission, 180
genome, 16
genotypes, 17
nanofiltration, 277
nucleic acid testing, 18, 175–176, 183, 189, 193–194
detection limits, 18, 193
United States approach, 204
pathogen inactivation, 19
plasma product risk assessment, 284
post-transfusion infection investigation, 312–313
risk assessment calculation, 332
risk factors, 16, 17, 18
serology, 18
seroconversion, 178
transfusion-transmission
fractionated products, 263, 266
risks, 18–19
window period, 18
see also GB virus C/hepatitis G virus (GBV-C/HGV)
hepatitis D virus (HDV), 13–15
characteristics, 13
clinical features, 14
definition, 13
diagnostic testing, 15
HBV coinfection see hepatitis B virus risk factors, 15
hepatitis E virus (HEV), 19–20
characteristics, 19
clinical features, 19
diagnostic testing, 19–20
risk factors, 20
seroprevalence rate, 19
vaccine, 20
window period, 20
hepatitis G virus (HGV) see GB virus C/hepatitis G virus (GBV-C/HGV)
hepatocellular carcinoma (HCC), hepatitis B virus, 13
hepatocyte, hepatitis effects, 10, 17, 19
herpes viruses, 35–58
human pathogens, 36
see also specific virus
high throughput automated assay, 210
HIV
blood donors
positive result notification, 317
re-admission, 181
fractionated products, removal from
ethanol fractionation, 275
immunofluorimetry chromatography, 276
nanofiltration, 276
GB virus C/hepatitis G virus coinfection, 77
human albumin safety, 285
immunoglobulin safety, 266
inactivation, 263, 270
Kaposi’s sarcoma-associated herpes virus, 78
leucocyte depletion, 239
post-transfusion infection investigation, 312–313
risk assessment calculation, 332, 333, 337
screening, 263–264
confirmatory algorithms, 176, 177
nucleic acid testing, 60, 193–194, 195, 203–204
plasma, 278
seroconversion, 210
transfusion
factor VIII, 272
investigation, 312–313
residual transmission risk(s), 312
see also specific types
HIV-1, 59–63
anti-HIV tests see anti-HIV tests
characteristics, 59
definition, 58
groups, 59
risk factors, 62
testing, 60–62
enzyme-linked immunosorbent assay, 60
fourth generation assays, 60, 164, 228
NAT, 60
third generation assays, 60
Western blot, 61
transfusion-transmission risk estimates, 62–63
viral transmission, 59–60
window period, 62
HIV-2, 59–63
characteristics, 59
definition, 59
discovery, 59
risk factors, 62
testing, 60–62
transfusion-transmission risk estimates, 62–63
viral transmission, 59–60
window period, 62
homosexual men, HIV risk, 62
hospital blood banks
definition, 368
European Union legislation, 367
human albumin see albumin, human
human erythroviruses see parovirus B19 (B19V)
human herpes virus-6 (HHV-6), 52
human herpes virus-7 (HHV-7), 52
human herpes virus-8 see Kaposi’s sarcoma-associated herpes virus (KSHV)
human immunodeficiency virus (HIV) see HIV
human T-cell leukaemia viruses (HTLV)
HTLV-I, 63–64
HTLV-II, 63–64
leucocyte depletion, 241
post-transfusion infection investigation, 312–313
screening, 176–178
human T-cell lymphotropic viruses (HTLV) see human T-cell leukaemia viruses (HTLV)
immune responses
complaints, 308
neonatogens, 247
immunoaffinity chromatography, 276
immunossay systems, 169–171
see also specific systems
immunofluorescence assay (IFA), KSHV
detection, 78
immunoglobulin(s), intravenous treatment
see also specific types
immunoglobulin M (IgM), 16
immunoglobulin(s), intravenous treatment

Subject index

Copyright © in this web service Cambridge University Press & Assessment

© in this web service Cambridge University Press & Assessment

www.cambridge.org
Subject index

influenza virus, 84
avian, 84
Innolia III, 175
intercept system, 108
platelet concentrate reduction, 106–107
internal quality assessment (IQA), 224
International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH), 1998, 246
intravenous immunoglobulin (IVIG) treatment hepatitis transmission, 265, 266
nanofiltration, 277
pepsin, 274
preparation methods, 265, 275, 276
safety, 265–267
hepatitis C transmission, 266–267
history, 265–266
HV transmission, 266
low pH treatment, 274
ion exchange chromatography, 276
Irish Blood Transfusion Service (IBTS), 31
Ixodes ricinus, 122, 123
Ixodes scapularis, 122
Ixodes ticks, 122
jaundice
hepatitis B virus, 13
hepatitis C virus, 17
Kala-azar, 127
Kaposi’s sarcoma-associated herpes virus (KSHV), 52–54, 77–80
characteristics, 77–78
CMV coexistence studies, 54
detection methods, 77, 78
endemicity, 53
epidemiology, 78–79
genomic organization, 77
HIV infection, 78
absence, 54
multiple myeloma, 78, 79, 80
seroconversion risk, seronegative vs. seropositive
blood, 53
seroprevalence rates, 53
transplantation, 79
kidney transplantation, 79
kinetic polymerase chain reaction (KPCR), 185
Kit Evaluation Groups (KEG), 165, 180
assay evaluation, 221
Koatech concentrate, 268, 271
KSHV see Kaposi’s sarcoma-associated herpes virus (KSHV)
Kuru, 141, 142
labile protein pasteurization, 270–271
laboratory staff
confidentiality, 319
knowledge/skills, 225–226
training, 228, 319
latex particles, particle agglutination assays, 167
Latin America, blood safety
costs, 376–378
demographics, 378
infectious disease markers prevalence, 376
transfusion services structure, 377
transfusion-transmissible infections, 377–378
Leishmania, 126–128
life cycle, 126
stored blood components, parasite survival, 127
transfusion-transmitted, 127
military cases, 127
Leishmaniasis, 126–128
serological tests, 127
leucocyte-depletion (LD), 239–241
bacteria, 241
benefits, 239
component quality effects, 241
cytomegalovirus, 239–241
filters, 94
human T-cell leukaemia viruses, 241
prion removal, 241
specifications, 239
variant Creutzfeldt–Jakob disease (vCJD), 241
Liberator®, 277, 278
ligase chain reaction (LCR), 186, 187
lipid-enveloped virus(es)
inactivation, 244, 272, 280
low pH treatments, 282
liver
biopsies, 326
SEN virus replication, 81
liver failure, hepatitis B, 13
look-back investigations, 314–315
Creutzfeldt–Jakob disease (CJD), 344
infection rates vs. clinical outcomes, 350
lot release, screening quality, 221–222
low pH treatment
immunoglobulin safety, 274
parvovirus B19, 282
virus inactivation processes, 274
virus validation studies, 282
Luck, Murray, 284
malaria, 117–119, 159
blood components, 119–122
donor questioning, 119–121
immigrants, 119
regulations, 119
remote endemic area recommendations, 120
screening problems, 120
post-transfusion infection investigation, 313
screening tests, 121–122
Vietnamese blood donor findings, 122
transfusion-transmitted see transfusion-transmitted malaria (TTM)
malignancy, blood donor selection criteria, 157
medicinal product legislation, European Union, 364–365
metabolomics, 229
methylene blue fresh frozen plasma (MBFFP), 249–250
clinical studies, 251–252
clotting factor levels, 250
microarrays, 229–233
benefits, 232
carbohydrate, 233
cell, 233
contact spotting, 232
design features, 230–232
DNA, 232–233
probes, 230
fluorescent detection, 232
multiple formats, 230–232
pathogen detection, 233–236
PCR and, 233
sensitivity, 232, 235
signal amplification methods, 232
substrates, 230
Microbiology in Blood Transfusion, 1
microporous membranes, 276
microvolume fluorimetry, 104–105
minimal deferment period, donor re-admission, 180
Mirusol system, platelet concentrate reduction systems, 107
misfolded protein diagnostic (MPD) assay, prion diseases, 149
monoclonal antibodies, production validation, 277
mortality, 351
mosquitoes, 117
multicentre Casselman’s disease (MCD), KSHV sequences, 78
multimer detection system, prion diseases, 150
multiple spotting technique (MIST), microarray technology, 236
multiplex PCRs, nucleic acid testing, 189, 198, 229, 233, 235
NANB hepatitis see hepatitis C virus (HCV)
nanocrystals, microarray sensitivity, 232
nanofiltration
prion removal, 286, 290
virus removal, 276–277
National Blood Service (UK), 209
archived samples, 312
assay evaluation, 221
blood donors positive results, 317
high throughput automated assays, 210
post-transfusion infection investigation, 311
staff, 319
National CJD surveillance Unit (NCJDSU), 144, 145
National Transfusion Microbiology Clinical Group, 317
‘near miss’ data collection, 308
neonatal carriers, 247
neonates
cytomegalovirus infection, exchange transfusion, 41
hepatitis B infection, 13
New York Blood Center (NYBC), solvent detergent treatment, 272
nitrogen mustard, 278
non-A, non-B (NANB) hepatitis virus, 9, 267, 274
non-haematological disease, parvovirus B19, 68
non-A, non-B (NANB) hepatitis virus, 9, 267, 274
non-lipid-enveloped viruses, 249, 280
non-HIV infected donors, 320
nucleic acid sequence based amplification (NASBA), 186
nucleic acid testing (NAT), 183–201, 228
amplicor detection, 211
amplification, 211
Ampliscreen system see Ampliscreen system anti-HCV coupling, 204–205
applications strategy, 183–191
assay requirements, 210–215
automated extraction, 211
automation, 200
contamination, 187–188
controls, 188

© in this web service Cambridge University Press & Assessment

www.cambridge.org
Subject index

prion diseases (cont.)
PRNP gene, 142
PrP*, 142, 143
PrPSc see PrPSc
pathophysiology, 143–144
peripheral blood infectivity
animal models, 144
blood transmission risk, 144–145
tissue products, 144–145
scrapie, 141, 142, 144
sporadic CJD see Creutzfeldt-Jakob disease (CJD)
testing, 148–149
transmissible mink encephalopathy, 141
transmission risk management strategies, 145–147
blood component processing, 147
cell products, 147
diagnostic/screening peripheral blood assay
development, 146–147
donor selection, 146
outsourcing blood/tissue practicalities, 146
plasma products, 147
tissue products, 147
variant CJD see variant Creutzfeldt-Jakob
disease (vCJD)
PRNP gene, 142
probability assignment, risk management, 342
process control, 217
assay design, 220
pathogen reduction, 254
validation, 224
Procleix TMA assay, 189, 209, 210
product safety margins, 246–247, 247
protein microarrays, 233
protein misfolding cyclic amplification
(PMCA), 149
protein precipitation, 275
proteomics, 229, 233
prothrombin complex concentrates (PCC), 277
protozoan parasites, 117–139
see also specific disease(s)
PrP, 142, 143
PrPSc see PrPSc
human, 142
PrPSc*, 143
PrPSc see PrPSc
diagnostic tests, 149, 150
immunoassay, 148
Pulse Management Software (PMS), 211
pure red cell aplasia (PRCA), parvovirus B19, 69
QiaGen system, 213
quality-adjusted life year (QALY), 356–357
quality assessment schemes (QAS), 222, 223–224
quality assurance, pathogen reduction, 254
quality control measures, 217
quality control samples, 222–223
stability, 223
statistical process monitoring, 223
validation, 224–225
quality improvement sources, 217
quality management, European Union legislation, 366
quantum dots, microarray sensitivity, 232
quarantine, samples, 225
radio-immune assay (RIA), 160
Radioimmunoprecipitation assay (RIPA), Chagas’ disease, 131
Rapid plasma reagin (RPR) tests, 166, 168
reactivity (screening), 219
falsely reactive results, 320
non-specific, 179–180, 312
reagents, assay design, 219
recombinant antigen, 227
recombinant coagulation factor
concentrates, 284
recombinant immunoblot assay-3 (RIBA), anti-HCV
testing, 174, 284
red blood cells)
inactivation systems, 107–109, 253
see also specific systems
reserved reduction, 68
reduction factors (pathogen reduction), 244, 245
fresh frozen plasma treatment, 246
prions, 287
regulatory environment, Europe, 363–368
organizations, 363–364
regulatory issues, 343–345
regulatory requirements
cost-effectiveness, 358
virus validation studies, 227–278
renal transplantation, KSHV risk, 79
residual transfusion risk(s), 228, 312, 348
anti-HBC, 25–26
blood safety, Africa, 375
hepatitis B virus, 25–26, 26
HAV, 312
nucleic acid testing, 193–194, 200, 203, 204
pathogen reduction treatments, 242
resonance light scattering (RLS), microarray
sensitivity, 232
respiratory viruses, 83–84
influenza virus, 84
severe acute respiratory syndrome, 84, 157, 284
Retrovirus Epidemiology Donor Study (REDS), 27,
342, 345
retroviruses, 58–65
see also specific retroviruses
reverse passive haemagglutination assays (RPHA), 168
reverse transcription, nucleic acid testing, 211
RIBA (recombinant immunoblot assay-3), 174, 204
riboflavine, 249, 253
ribonucleic acid, hepatitis C virus see hepatitis C
virus (HCV)
risk assessments, 334–335, 343, 356
blood donor selection criteria, health damage, 155–156
calculations, 330–340
advantages, 338
false-negative tests, 331
infection surveillance, 331–333
limitations, 336–338
methods, 333–336
nucleic acid testing, 338
process error, 331
seroconversion, 332, 336–337
sero-negativity, 331
usage, 330–336
window periods, 333–334, 346–348, 349
categories, 341
definition, 341–342
fractionated products, 283–284
studies, prospective, 329–340
advantages, 330
limitations, 328–330
rewards, 330
risk characterization, 343–345
risk identification, 343–345
risk management, 341–361
autologous blood transfusion, 353
cardiac surgery, 345
case control studies, 344
communication, 343, 355–356
cost-effectiveness analysis, 356–357
definition, 342–343
direct measurement of risk, 345
infection rate vs. clinical outcomes, 350–351
interventions, 343
modelling, 345
prions see prion diseases
probability assignment, 342
psychometric studies, 354
risk assessment see risk assessments
risk per unit vs. risk per patient, 348, 350
simulation model, 342, 345–348
risk modelling, 345–348
risk perception, 353–354, 355
risk reduction measures, 351–353
roboric systems, 167
Roche Cobas Amplicore system, 209
Roche Cobas Core II system, 171
rodent cell lines, recombinant coagulation factor
concentrates, 285
rolling circle amplification (RCA), microarray
technology, 232, 235
S59 see amotosalen (S59)
S-303
scrapie, 141, 142, 144
screening, 227–238
bacteria challenges, 94–95
blood/blood components systems, 98–100
complexity, 228
cost, 228
developments, 228–229
features, 227
issues, 95
methods see screening methods
non-specific reactivity, 179–180
platelets, 101
quality see screening quality
regulatory issues, 236–237
safety, 228
serology, 227–228, 229, 235–236
screening methods, 159–172, 227–228
assay performance, 165
future developments, 320–321
HBsAg testing, 14
history, ... 313
strains, 128
transmission, 128
viability, 129
trypanosomiasis, American
see Chagas’ disease
389
Subject index
Subject index

**TT virus (TTV)** see *torquetenovirus (TTV)*

tyramide signal amplification (TSA), microarrays, 232

UK Blood Services Microbiology Kit Evaluation Groups see Kit Evaluation Groups (KEG)

UK Blood Transfusion Guidelines (2002), 180

UK hepatitis C national register, 323–327

comparative data sources, 324

enrolment, 323–324

information required, 324

morbidity, 324–326

mortality, 324–326

patient distribution, 325

patient follow-up, long-term, 324

recruitment, 323–324

as a resource, 326

ultraviolet light

UVA, 247–249

UVB, 249

virus inactivation, 270

vaccine/vaccination

haemophilia, 271

hepatitis A virus, 12

hepatitis B virus, 16

hepatitis e virus, 20

hepatitis transmission, 262

parvovirus B19, 69, 70

validation

screening quality, 217, 224–225

manufacturer’s criteria, 224

quality control sample results, 224

user criteria, 224

virus studies, 277–283

design, 278, 280

down-scaled process establishment, 281

dry heat treatment, 282

fractionated products, 277–282

low pH treatment, 282

process parameters, 280, 283

regulatory requirements, 277–278

results interpretation, 282

solvent detergent treatment, 282

viral selection, 280–281

variant Creutzfeldt-Jakob disease (vCJD), 147, 285

blood filtration, 241

diagnostic assays, 148

development, 148, 150

see also specific assays

incidence, 141

infective dose, 287

leucocyte depletion, 241

plasma fractionation, 260

risk management, 342, 352

transfusion-transmission, 147

venepuncture sites, bacterial infection, 314

Venereal Disease Reference Laboratory (VDRL), 166

Vidas immunoassay system, 171

Virus inactivation, 353

Virology, 372

Virology and virological tests, 270

virus(es)

emerging

fractionated products, 284

pathogen reduction treatments, 242

fractionated products, removal from, 275–277

adsorption, 273–276

precipitation, 275

recombinant coagulation factor concentrates elimination, 285

transmission, 285

see also specific viruses

virus inactivation, 353

historical aspects, 270

processes

chemicals, 270

dry heat treatment, 276–277

fractionated products, 270–274, 277

labile protein pasteurization, 270–271

low pH treatment, 274

solvent detergent treatment, 272–274

HIV irradiation, 279

visible light, pathogen reduction treatment, 242

Vitros Eci immunoassay system, 171

von Willebrand factor

cleaving protease, 252

levels, 251, 252

WA-1 infections, humans, 123

water baths, blood product contamination, 89

Western blot(s)

Chagas’ disease, 131

HIV-1, 61

KSHV detection, 78

nucleic acid testing vs., 203

prion removal, 286

Westguard rules, statistical process monitoring, 223

West Nile virus (WNV), 82–83, 284, 344

blood supply protection, 85

characteristics, 4–5, 82–83

infection, 206, 207

nucleic acid testing, United States approach, 205

outbreak locations, 82

risks, 5

RNA detection, 83

transfusion, 83

‘window donations,’ definition, 183

window period(s) (WP)

hepatitis A virus, 11

hepatitis B virus, 15

hepatitis C virus, 18

hepatitis E virus, 20

HIV, 62

human T-cell leukaemia viruses, 64

risk assessment, incidence calculation, 333–334, 346–348, 349

limitations, 347–348

Schreiber incidence, 26

trophs, 110

World Health Organization (WHO), 363

Yersinia enterocolitica, 241

donor bacteraemia, 88

transfusion-transmission reduction strategies, 91

8Y treatment, 272